Donor IL-18 Rs5744247 Polymorphism as a New Biomarker of Tacrolimus Elimination in Chinese Liver Transplant Patients During the Early Post-Transplantation Period: Results from Two Cohort Studies
- 25 February 2015
- journal article
- Published by Taylor & Francis Ltd in Pharmacogenomics
- Vol. 16 (3), 239-250
- https://doi.org/10.2217/pgs.14.166
Abstract
This study evaluated the relationships between IL-18 polymorphisms and tacrolimus elimination in Chinese liver transplant patients. Eighty-four liver transplant patients from Shanghai (training set) and 50 patients from Shandong (validating set) were inculded. IL-18 polymorphisms (rs5744247, rs7106524, rs549908, rs187238 and rs1946518) and CYP3A5 rs776746 were genotyped. In training set, daily drug dose, total bilirubin, donor CYP3A5 rs776746 and IL-18 rs5744247 genotypes were screened to construct prediction model for tacrolimus elimination. This model was confirmed in validating set (p < 0.001). Donor IL-18 rs5744247 polymorphism was an independent predictor of tacrolimus elimination in the first week after transplantation in both training (p = 0.008) and validating cohorts (p = 0.033). Donor IL-18 rs5744247 polymorphism may influence on tacrolimus elimination. Original submitted 16 July 2014; Revision submitted 12 November 2014.Funding Information
- National Natural Science Foundation of China (81202609, 81170446)
- Shanghai Jiaotong University (YG2012MS05)
This publication has 45 references indexed in Scilit:
- Influence of TLR4 rs1927907 locus polymorphisms on tacrolimus pharmacokinetics in the early stage after liver transplantationEuropean Journal of Clinical Pharmacology, 2014
- Liver Transplantation — A Vision RealizedNew England Journal of Medicine, 2012
- Pharmacogenetic biomarkers: cytochrome P450 3A5Clinica Chimica Acta; International Journal of Clinical Chemistry, 2012
- Immunomodulating Therapy in Liver Transplantation: Principles and PracticeImmunotherapy, 2012
- Immunomodulating options for liver transplant patientsExpert Review of Clinical Immunology, 2012
- A Systematic Review of the Effect of CYP3A5 Genotype on the Apparent Oral Clearance of Tacrolimus in Renal Transplant RecipientsTherapeutic Drug Monitoring, 2010
- Cardiovascular Risk Factors and Immunosuppressive Regimen After Liver TransplantationTransplantation Proceedings, 2010
- Recipient-Based Approach to Tailoring Immunosuppression in Liver TransplantationTransplantation Proceedings, 2010
- Long-term outcomes of liver transplantation: Diabetes mellitusLiver Transplantation, 2009
- Dual Mechanisms of CYP3A Protein Regulation by Proinflammatory Cytokine Stimulation in Primary Hepatocyte CulturesPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2009